INFECTIONS AND OTHER LUNG DISEASES USING MODELS OF HUMAN LUNG TISSUE GROWN FROM STEM CELLS
Dr Rhiannon Werder,
Team Leader
Murdoch Children’s Research Institute
Melbourne, Victoria, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | February 2025
Released on the United Nations International Day of Women and Girls in Science, 11th February 2025 @WomenScienceDay
Dr Rhiannon Werder is a Team Leader at Murdoch Children’s Research Institute leading a multidisciplinary team, combining expertise in stem cell biology and immunology, to develop new therapies for lung diseases. Her research centres around induced pluripotent stem cells to investigate respiratory diseases, spanning acute respiratory infections to chronic lung diseases. Using stem cells, Dr Werder’s team creates models of human lung tissue. With these models, Dr Werder is investigating how human-specific pathogens infect different regions of the lung, the ensuing immune responses, and how the lung repairs itself after infections, especially in people with preexisting lung diseases.
After completing her PhD in Mucosal Immunology at the University of Queensland, Dr Werder was awarded a NHMRC CJ Martin Fellowship to undertake postdoctoral training at the Center for Regenerative Medicine at Boston University. At the height of the COVID-19 pandemic, Dr Werder’s research led to significant findings, including the first discovery of how the lung epithelium responds to the SARS-CoV-2 virus. She has also pioneered new gene-editing techniques in iPSC-derived epithelial cells to understand chronic lung disease inception. The impact of her research has been recognised by prestigious awards including the Metcalf Prize for Stem Cell Research by National Stem Cell Foundation of Australia.
You Might also like
-
Cellular mechanisms of traumatic brain injury & concussion
Professor Melinda Fitzgerald is Deputy Vice Chancellor, Research at Curtin University, John Curtin Distinguished Professor and CEO of Connectivity Traumatic Brain Injury Australia.
She has published over 135 papers; recent highlights include Lancet Neurology, J Neuroscience, Nature Nano, ACS Nano, Biomaterials. Currently held grants/Projects total $10.1 million; CIA for $5.2 million of these; $18.5 million total research and equipment funding, $9.9 million as CIA; continuous category 1 grant funding as CIA since 2009.
-
Superslayer taking on antibiotic-resistant bacteria
Dr Katharina Richter is a visionary leader in MedTech, acclaimed for innovation and gender diversity. With over 40 awards to her name, including MIT Innovator Under 35 Asia-Pacific, and Prime Minister’s Prize for New Innovator finalist, she has shattered barriers as an entrepreneur, scientist, and ‘superbug slayer.’ Katharina’s groundbreaking work in combating antibiotic-resistant bacteria has resulted in 6 innovative treatments, 3 of which are patented, offering hope against deadly infections.
-
Role of Community Paramedicine in Non-Emergency Presentations
Dr Robbie King is a Lecturer in paramedicine and researcher at the Australian Catholic University (ACU) Brisbane. He also continues to provide clinical care as a registered paramedic for community members served by a jurisdictional ambulance service. Dr King has gained significant experience working in an advanced practice, community paramedic style role, holding expert clinical insight into the nuances of paramedic-led community-based healthcare for non-emergency presentations. This often involves adopting a biopsychosocial approach, rather than following the biomedical model more associated with emergency medicine and paramedic culture.
https://orcid.org/0000-0002-6432-4587